The global plasma fractionation market size accounted for USD 36,100 million in 2024 and is predicted to touch around USD 80,130 million by 2034, growing at a CAGR of 8.30% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 39,100 Million |
| Market Size by 2034 | USD 80,130 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 8.30% |
Plasma fractionation is a general process of separating the multiple components of blood plasma into its constituent proteins. This process helps in the development of various life-saving protein therapies for the increasing global population of people above 60 years of age. The growing number of various disorders like immunodeficiencies and the rapid increase in the demand for plasma-derived products boost the plasma fractionation market growth.
The rapid increase in blood collection facilities and increase in plasma therapies like immunoglobulin treatments, coagulation factors, and albumin also contribute to the market growth.
“It is an honor for Grifols to once again be recognized in the Dow Jones Sustainability Index as one of the world’s most sustainable companies. “As we continue to deliver consistently strong financial and operational performance, we are very much focused on our commitment to achieving best-in-class ESG practices and our 2030 goals.”
“This year, we manufactured an extra 100,000 flu vaccines to ensure there were enough doses for every person who wants to be vaccinated. It’s always a source of pride to know that flu vaccines, including those manufactured in Melbourne, are helping protect people from serious complications of flu, as well as helping reduce the burden on clinics and hospitals.”
North America
North America dominated the plasma fractionation market in 2024. The presence of leading global companies with specializations in plasma fractionation processes, with the rising number of startup companies and plasma research institutes related to plasma medicine, contribute to the growth of the market. The region experiences a rapidly growing number of patients with chronic diseases and respiratory disorders, due to which the awareness of plasma treatment has increased with government initiatives and investments in the biopharmaceutical industry.
APAC
Asia-Pacific region is predicted to be the fastest-growing region to contribute to the plasma fractionation market in the forecasted period of 2025-2034. The growth is the result of new and advanced scientific developments in the healthcare sector. Government initiatives and investment in the healthcare sector also play a vital role in the growth of the plasma fractionation market.
The plasma fractionation market is highly competitive, with leading players all across the globe. Some of the leading players in the markets include Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., and Biotest AG, which hold the biggest market share for the plasma fractionation market.
The market is dominated by several companies, but the companies that are renowned for their contribution in the market are listed below:
Grifols S.A. is a leading global healthcare company specializing in plasma-derived medicine and healthcare solutions. The company focuses on four major therapeutic areas: immunology, infectious diseases, pulmonology, and critical care.
CSL Ltd. Is a leading global biopharmaceutical company engaged in research & development and the manufacturing of market vaccines and plasma protein biotherapies. The company recorded a revenue of US$ 2,642 million in 2024.
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company specializing in patient-focused research & development in oncology, rare diseases, plasma-derived therapies & vaccines, neuroscience, and gastroenterology.
Published by Kesiya Chacko
